Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Claims19
A pharmaceutical composition comprising:
- a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a Collagen alpha-1 (VII) chain polypeptide;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the Infected Cell Protein (ICP) 4 herpes simplex virus gene.
A pharmaceutical composition comprising:
- a) a herpes simplex type 1 virus (HSV-1) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a Collagen alpha-1 (VII) chain polypeptide;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the HSV-1 has reduced cytotoxicity as compared to a wild-type herpes simplex type 1 virus.
A pharmaceutical composition comprising:
- a) a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a Collagen alpha-1 (VII) chain polypeptide;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the Collagen alpha-1 (VII) chain polypeptide comprises an amino acid sequence having at least 90% identity to the sequence of SEQ ID NO:
- 2;
- and
- wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
Dependencies are inferred from the claim text.